HR-3491-119
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Diana DeGette (D-CO)
What it does
This bill would amend the Public Health Service Act to formally authorize the NIH Director to carry out the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. The program would fund research, training, and investigation into Down syndrome across seven defined areas, including clinical trials, biomarker identification, co-occurring conditions such as Alzheimer's disease and autoimmune disorders, and quality-of-life improvements. The NIH Director would be required to coordinate research across NIH institutes, avoid duplication, consult with patient advocates, and submit biennial reports to Congress.
Who benefits
The approximately 200,000 Americans currently living with Down syndrome and their families, who would benefit from improved treatments, therapies, and quality-of-life research. Researchers and academic institutions that would receive NIH grants and training opportunities. Pharmaceutical and biotech companies developing novel therapies for Down syndrome and related conditions. Patients with co-occurring conditions studied under the program — particularly those with Alzheimer's disease and autoimmune disorders — who may benefit indirectly from research findings. Patient advocacy organizations that would gain a formal consultative role in NIH priority-setting.
Who is hurt
Researchers and institutions working on other NIH-funded conditions who may face increased competition for limited NIH resources if appropriators shift funding toward this program. Taxpayers who would bear the cost of any new appropriations, though the bill does not specify a dollar amount. Other disease-specific research communities that lack comparable statutory authorization and may be disadvantaged in NIH priority-setting relative to a congressionally mandated program.
Supporters argue
Supporters argue that Down syndrome affects roughly 1 in 700 births in the United States and that individuals with the condition face dramatically elevated rates of Alzheimer's disease — with nearly all developing the pathology by age 40 — making coordinated federal research both urgent and scientifically productive. They contend that the INCLUDE Project, which NIH launched administratively in 2018, has already demonstrated results but lacks the statutory permanence and congressional oversight that would ensure sustained funding and accountability. Formalizing the program in law, they argue, would protect it from administrative discontinuation and require regular reporting to Congress on real-world outcomes.
Opponents argue
Opponents argue that Congress should not single out individual diseases for statutory research mandates, as doing so distorts NIH's peer-review-driven priority-setting process and may disadvantage equally serious conditions that lack political visibility. They contend that the INCLUDE Project already operates without statutory authorization, suggesting the bill adds bureaucratic reporting requirements without meaningfully increasing research capacity, and that any new appropriations directed here come at the opportunity cost of other unfunded medical research priorities. Critics may also note that the bill authorizes the program without specifying a funding level, leaving its fiscal impact uncertain and potentially nominal.
Constitutional context
Congress has broad authority to fund biomedical research through the Taxing and Spending Clause (Art. I, §8, cl. 1) and to regulate the activities of federal agencies like NIH under the Necessary and Proper Clause (Art. I, §8, cl. 18). No significant constitutional challenge is apparent for this type of direct federal research authorization.
Checks and balances
The executive branch (NIH Director) gains a formal statutory mandate to run this program; Congress retains oversight through mandatory biennial reports to four committees and controls funding levels through the annual appropriations process.
Historical precedent
Congress has previously enacted disease-specific research mandates within the Public Health Service Act, such as the National Alzheimer's Project Act (2011), which similarly directed NIH coordination and reporting on a specific condition.